Company or ticker...

BioTech

UroGen Pharma

UroGen Pharma develops and commercializes treatments for urothelial cancers using localized drug-delivery technology that turns liquid medicines into a gel inside the urinary tract, allowing the drug to remain in contact with tumors for longer periods.

Ticker

M. Cap

PS

PE

YTD

10MA

20MA

50MA

200MA

URGN

1.4B

5.5

n/a

18.57%

Key Facts

M. Cap

PS

PE

YTD

1.4B

5.5

n/a

18.57%

10MA

20MA

50MA

200MA

$URGN